SEC ownership of OptimizeRx Corp

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001448431.

Comparable stake leader

Whetstone Capital Advisors, LLC

Disclosed value leader

Whetstone Capital Advisors, LLC

Comparable rows

50/50

Latest evidence

09 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Whetstone Capital Advisors, LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
09 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001448431
Issuer location
Waltham, MA

Ownership snapshot

Top shareholders of OptimizeRx Corp (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Whetstone Capital Advisor...
Disclosed value leader
Whetstone Capital Advisor...
Comparable rows
50/50
Latest evidence
09 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 8.2% 13D/G row: Whetstone Capital Advisors, LLC Showing 1-8 of 50 holder rows.

Quick read

Whetstone Capital Advisors, LLC leads the comparable SEC ownership view at 8.2%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Whetstone Capital Advisors, LLC's linked filing trail.
Comparable ownership Top 5
Whetstone Capital Advisors, LLC 8.2%
ROYCE & ASSOCIATES LP 4.3%
Samjo Management, LLC 0%
James Paul Lang 2.3%
Vos Ellen O'Connor 0.58%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Whetstone Capital Advisors, LLC
13D/G 13F
Company
8.2%
$13,061,904
1,508,303 shares
$0 18 Apr 2025
ROYCE & ASSOCIATES LP
13D/G 13F
Company
4.3%
$10,673,640
790,640 shares
-$3,765,420 30 Jun 2025
Samjo Management, LLC
13D/G
0%
$433
50 shares
$0 31 Dec 2024
James Paul Lang
3/4/5
Director
2.3%
$2,724,496
433,837 shares
09 Jun 2026
Vos Ellen O'Connor
3/4/5
Director
0.58%
$672,958
107,159 shares
09 Jun 2026
Gregory D. Wasson
3/4/5
Director
0.49%
$575,876
91,700 shares
09 Jun 2026
Patrick D. Spangler
3/4/5
Director
0.42%
$494,436
78,732 shares
-$194,489 09 Jun 2026
Cathy Klema
3/4/5
Director
0.3%
$352,540
56,137 shares
09 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$224,864.

Buys
$0
Insiders: 0
Sells
$224,864
Insiders: 2
Net
-$224,864
Shares: -12,740
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 12,740
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 1,620 $0 $30,375 -$30,375
9-12 0 11,120 $0 $194,489 -$194,489

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to OptimizeRx Corp. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Miriam J. Paramore
Net 12M change
-$224,864
Latest report
09 Jun 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Miriam J. Paramore President And Cso $5,568,610 Mixed 02 Dec 2021
William J. Febbo CEO, Director $4,608,010 Mixed 14 Feb 2025
Douglas P. Baker Chief Financial Officer $2,763,393 Mixed 05 Oct 2021
James Paul Lang Director $2,724,496 Median 09 Jun 2026
Edward Stelmakh Chief Finance & Strat Officer $1,681,283 Mixed 23 Dec 2025
Stephen L. Silvestro Chief Executive Officer $1,163,608 -$30,375 -2.5% Median 15 May 2026
Doug Besch Chief Product & Tech Officer $894,030 Mixed 23 Dec 2025
Gus D. Halas Director $865,908 Mixed 05 Jun 2024
Marion K. Odence-Ford Chief Legal & Admin Officer $848,569 Mixed 11 Feb 2026
Vos Ellen O'Connor Director $672,958 Median 09 Jun 2026
Andrew J. D'Silva Chief Business Officer $604,369 Mixed 19 Dec 2025
Gregory D. Wasson Director $575,876 Median 09 Jun 2026
Patrick D. Spangler Director $494,436 -$194,489 -28% Median 09 Jun 2026
Theresa Greco Chief Commercial Officer $446,351 Median 15 May 2026
Brendan W. Merrell Chief Operating Officer $354,056 Mixed 19 Dec 2025
Cathy Klema Director $352,540 Median 09 Jun 2026
Mariyamma Varghese Presti Director $190,397 Median 09 Jun 2026
Brian Clark McCarthy Chief Revenue Officer $102,003 Mixed 02 Aug 2024
Todd Inman Chief Technology Officer $30,548 Mixed 01 Mar 2023

Recent insider transactions for OptimizeRx Corp

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Cathy Klema OPRX Common Stock Award 159.6% 34,517 56,137 09 Jun 2026 Direct
James Paul Lang OPRX Common Stock Award 8.64% 34,517 433,837 09 Jun 2026 Direct
Mariyamma Varghese Presti OPRX Common Stock Award 132.1% 17,258 30,318 09 Jun 2026 Direct
Patrick D. Spangler OPRX Common Stock Award 78.1% 34,517 78,732 09 Jun 2026 Direct
Vos Ellen O'Connor OPRX Common Stock Award 47.5% 34,517 107,159 09 Jun 2026 Direct
Gregory D. Wasson OPRX Common Stock Award 60.4% 34,517 91,700 09 Jun 2026 Direct
Theresa Greco OPRX Common Stock Tax liability -2.46% -1,793 71,075 15 May 2026 Direct
Stephen L. Silvestro OPRX Common Stock Tax liability -2.74% -5,219 185,288 15 May 2026 Direct
Mariyamma Varghese Presti OPRX Common Stock Award 13,060 13,060 01 May 2026 Direct
Marion K. Odence-Ford OPRX Common Stock Tax liability -1.49% -1,386 91,936 11 Feb 2026 Direct
Marion K. Odence-Ford OPRX Common Stock Options Exercise 4.48% 4,000 93,322 11 Feb 2026 Direct
Marion K. Odence-Ford OPRX Restricted Stock Units Options Exercise -100% -4,000 0 11 Feb 2026 Direct
Stephen L. Silvestro OPRX Common Stock Tax liability -1.73% -3,361 190,507 23 Dec 2025 Direct
Theresa Greco OPRX Common Stock Tax liability -1.91% -1,420 72,868 23 Dec 2025 Direct
Marion K. Odence-Ford OPRX Common Stock Tax liability -4.34% -4,051 89,322 23 Dec 2025 Direct
Doug Besch OPRX Common Stock Tax liability -5.75% -4,079 66,876 23 Dec 2025 Direct
Edward Stelmakh OPRX Common Stock Tax liability -2.88% -3,658 123,172 23 Dec 2025 Direct
Edward Stelmakh OPRX Common Stock Tax liability -1.08% -1,388 126,830 19 Dec 2025 Direct
Edward Stelmakh OPRX Common Stock Options Exercise 4.26% 5,237 128,218 19 Dec 2025 Direct
Edward Stelmakh OPRX Restricted Stock Units Options Exercise -50% -5,237 5,237 19 Dec 2025 Direct
Stephen L. Silvestro OPRX Common Stock Tax liability -0.82% -1,594 193,868 19 Dec 2025 Direct
Stephen L. Silvestro OPRX Common Stock Options Exercise 3.47% 6,546 195,462 19 Dec 2025 Direct
Stephen L. Silvestro OPRX Restricted Stock Units Options Exercise -50% -6,546 6,547 19 Dec 2025 Direct
Marion K. Odence-Ford OPRX Common Stock Tax liability -1.22% -1,153 93,373 19 Dec 2025 Direct
Marion K. Odence-Ford OPRX Common Stock Options Exercise 4.34% 3,928 94,526 19 Dec 2025 Direct
Marion K. Odence-Ford OPRX Restricted Stock Units Options Exercise -50% -3,928 3,928 19 Dec 2025 Direct
Brendan W. Merrell OPRX Common Stock Tax liability -1.09% -289 26,207 19 Dec 2025 Direct
Andrew J. D'Silva OPRX Common Stock Tax liability -1.55% -703 44,735 19 Dec 2025 Direct
Doug Besch OPRX Common Stock Tax liability -0.81% -581 70,955 19 Dec 2025 Direct
Doug Besch OPRX Common Stock Options Exercise 2.82% 1,964 71,536 19 Dec 2025 Direct
Doug Besch OPRX Restricted Stock Units Options Exercise -50% -1,964 1,964 19 Dec 2025 Direct
Brendan W. Merrell OPRX Common Stock Tax liability -2.62% -712 26,496 11 Dec 2025 Direct
Andrew J. D'Silva OPRX Common Stock Tax liability -1.87% -868 45,438 11 Dec 2025 Direct
Theresa Greco OPRX Common Stock Tax liability -2.23% -1,693 74,288 01 Nov 2025 Direct
Brendan W. Merrell OPRX Common Stock Tax liability -1.74% -483 27,208 03 Oct 2025 Direct
Andrew J. D'Silva OPRX Common Stock Tax liability -1.69% -794 46,306 03 Oct 2025 Direct
Marion K. Odence-Ford OPRX Common Stock Tax liability -2.11% -1,952 90,598 03 Oct 2025 Direct
Marion K. Odence-Ford OPRX Common Stock Options Exercise 7.74% 6,649 92,550 03 Oct 2025 Direct
Marion K. Odence-Ford OPRX Restricted Stock Units Options Exercise -100% -6,649 0 03 Oct 2025 Direct
Stephen L. Silvestro OPRX Common Stock Sale -0.85% $30,375 $18.75 -1,620 188,916 03 Oct 2025 Direct
Stephen L. Silvestro OPRX Common Stock Options Exercise 3.62% 6,649 190,536 03 Oct 2025 Direct
Stephen L. Silvestro OPRX Restricted Stock Units Options Exercise -100% -6,649 0 03 Oct 2025 Direct
Edward Stelmakh OPRX Common Stock Tax liability -3.46% -4,406 122,981 03 Oct 2025 Direct
Edward Stelmakh OPRX Common Stock Options Exercise 15% 16,623 127,387 03 Oct 2025 Direct
Edward Stelmakh OPRX Restricted Stock Units Options Exercise -100% -16,623 0 03 Oct 2025 Direct
Doug Besch OPRX Common Stock Tax liability -1.39% -983 69,572 03 Oct 2025 Direct
Doug Besch OPRX Common Stock Options Exercise 4.95% 3,325 70,555 03 Oct 2025 Direct
Doug Besch OPRX Restricted Stock Units Options Exercise -100% -3,325 0 03 Oct 2025 Direct
Andrew J. D'Silva OPRX Common Stock Tax liability -0.87% -414 47,100 01 Oct 2025 Direct
Patrick D. Spangler OPRX Common Stock Sale -20.1% $194,489 $17.49 -11,120 44,215 28 Aug 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .